A group of researchers from the Dana-Farber Cancer Institute (MA, USA) has conducted the largest clinical study to date of genetic abnormalities in pediatric brain tumors. The study, published recently in Neuro-Oncology, highlighted that testing for genetic irregularities is clinically feasible and that the results could help guide patients’ treatment.
Restricted Content / Members Only
You cannot view this content because It is available to members only. Please Login or Register to view this area.